ClinicalTrials.gg
Active, not recruitingNCT03673124Updated Dec 23, 2025Results posted

Ribociclib and Letrozole Treatment in Ovarian Cancer

A Phase 2 interventional study of Ribociclib and Letrozole in Low Grade Serous Carcinoma, sponsored by Gynecologic Oncology Group. Active, not recruiting at 27 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Gynecologic Oncology Group · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

Read the detailed description

Ribociclib (formerly LEE011) is an orally bioavailable, highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Ribociclib has been approved by the United States Food and Drug Administration (U.S. FDA) and the European Commission as an initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor based on a randomized, double-blind, placebo-controlled, international clinical trial (MONALEESA-2). Additional marketing authorizations are under review by health authorities. Additional phase III clinical trials for the treatment of hormone receptor positive (HR+) breast cancer patients, as well as several other phase I or II clinical studies are being conducted.

Letrozole is a highly potent, orally active non-steroidal competitive inhibitor of the aromatase enzyme system. It effectively inhibits the conversion of androgens to estrogens both in vitro and in vivo. It is indicated both as first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer as well as for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Based on encouraging results in women with advanced hormone-receptor-positive breast cancer, a clinical trial for women with recurrent low-grade serous carcinoma is warranted. Furthermore, such a trial would have great appeal to women with recurrent low-grade serous carcinoma, a cohort with limited therapeutic options. Although low-grade serous carcinoma is a rather uncommon histologic subtype, prolonged overall survival results in a relatively high prevalence.

02

Conditions studied

  • Low Grade Serous Carcinoma

Keywords

  • ovary
  • peritoneum
  • fallopian tube
03

In context

Cystadenocarcinoma, Serous

15 studies on the registry are indexed under Cystadenocarcinoma, Serous; 1 is open to participants now.

This study's enrollment of 51 is close to the median of 52 across 13 interventional studies indexed under Cystadenocarcinoma, Serous.

Browse Cystadenocarcinoma, Serous studies →

Lead sponsor

Gynecologic Oncology Group is the lead sponsor of 188 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Patients eligible for inclusion in this study must meet all of the following criteria:

  1. Patient has signed the (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements.
  2. Age > 18 years at time of study entry.
  3. Willingness and ability to comply with study and follow-up procedures.
  4. Histological confirmation of diagnosis of low-grade serous carcinoma of ovary, fallopian tube or peritoneum; Original diagnosis of de novo low-grade serous carcinoma or Original diagnosis of serous borderline tumor with subsequent diagnosis of low-grade serous carcinoma.

    • In order to prevent inclusion of patients with high-grade serous carcinoma, diagnosis of low-grade serous carcinoma will be verified as part of screening review by a gynecologic pathologist. Tissue for confirmation can be from primary tumor or recurrence.
  5. Patient must have recurrent, by v1.1.
  6. There are no restrictions on number of prior therapies.
  7. Patient cannot have previously received a prior cyclin dependent kinase inhibitor (CDKi). Patients who were treated with letrozole or another aromatase inhibitor for other indications must have not taken the drug for 6 months prior to initiating letrozole for this trial and may not have progressed on treatment.
  8. Patients must not have remaining ovarian function to be included. In women who have at least one retained ovary, menopause must be confirmed with laboratory confirmation. Women who have ovarian function are eligible but must be placed on hormonal suppression. Menopause must be confirmed with laboratory confirmation, to include an estradiol level as this is assessed within 8 weeks of patient having been on tamoxifen.
  9. (ECOG) performance status (PS) 0-2
  10. Resolution of all acute toxic effects of prior therapy or surgical procedures to National Cancer Institute (NCI) Grade ≤ 1. Patients with grade 1 taxane-induced neuropathy, any grade alopecia, amenorrhea, or other toxicities not considered a safety risk for the patient as per investigator's discretion are eligible. 1. Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:

    • ≥1.5 × 109/L
    • ≥100 × 109/L
    • ≥9.0 g/dL
    • Potassium, total calcium (corrected for serum albumin), magnesium, sodium and phosphorus within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication
    • International Normalized Ration () ≤1.5 (unless patient is receiving permitted anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within 7 days prior to the first dose of study drug). Serum creatinine \<1.5 mg/dL or ≥50 mL/min
    • In the absence of liver , (ALT) and aspartate aminotransferase (AST) \<2.5 x (ULN). If the patient has liver metastases, ALT and AST \<5 x ULN
    • Total \< ULN; or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome.

12. Patient with available standard 12-lead with the following parameters at screening:

  • interval at screening \<450msec (using Fridericia's correction)
  • Resting heart rate 50-90bpm 13. Must be able to swallow ribociclib and letrozole capsules/tablets. 14. Patients receiving tamoxifen or toremifene must have of 5 half-lives prior to randomization.

Patients eligible for this study must not meet any of the following criteria:

  1. Patient has a known to any of the of ribociclib or letrozole.
  2. Patient has a concurrent or malignancy within 3 years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer. Patients with known are excluded.
  3. Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:

    • At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
    • Clinically stable CNS tumor at the time of screening and not receiving and/or enzyme inducing anti-epileptic medications for brain metastases.
  4. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  5. Patient has a known history of infection (testing not mandatory).
  6. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
  7. , uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:

    • History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening
    • History of documented congestive heart failure ( functional classification III-IV)
    • Documented cardiomyopathy
    • (LVEF) \<50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade Atrioventricular (AV) block (e.g. bifascicular block, Mobitz type II and third-degree AV block)
    • Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

      • Risk factors for Torsades de Pointe (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
      • Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication
      • Inability to determine the QT interval on screening (QTcF, using Fridericia's correction)
      • Systolic blood pressure (SBP) >160 mmHg or \<90 mmHg at screening
  8. Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug (see Table 1 for details):

    • Known strong inducers or inhibitors of /5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges
    • That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
    • Herbal preparations/medications, dietary supplements.
  9. Participation in other studies involving drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational product (whichever is longer) or participation in any other type of medical research judged not to be scientifically or medically compatible with this study. If the patient is enrolled or planned to be enrolled in another study that does not involve an investigational drug, the agreement of Novartis study medical lead is required to establish eligibility.
  10. Patient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed. Direct-Acting Oral Anticoagulants (DOACS) are permitted.
  11. Patient is currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment. The following uses of corticosteroids are permitted: a short duration (,5 days) of systemic corticosteroids; any durations of topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
  12. Patient who has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated.
  13. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor is not considered as major surgery).
  14. Patient with a score B or C.
  15. Patients who are pregnant or breastfeeding.
  16. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of throughout the study and for 3 weeks after study drug discontinuation. Highly effective contraception methods include:

    • Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment

    Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

  17. Current use of food or drugs known to be potent CYP3A4 inhibitors, drugs known to be potent CYP3A4 inducers, and drugs that are known to prolong the QT interval unless the prohibited concomitant medication can be replaced by other drugs of less potential to inhibit or induce CYP3A4 or prolong QT interval (See Appendix C for Prohibited Concomitant Medications).
  18. Patients whose tumors contain both low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC)
  19. Patients with history of haemopoietic stem cell or bone marrow transplant.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Other
    Ribociclib and letrozole

    Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily

    Drug: Ribociclib · Drug: Letrozole

Interventions

  • 600 mg by mouth daily for 21 days followed by 7 days off treatment

  • 2.5 mg by mouth daily

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants in the analysis population who achieved a complete response or partial response, as assessed by RECIST 1.1.

    Time frame: Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants in the analysis population who achieved a complete response, partial response, or stable disease, as assessed by RECIST 1.1.

    Time frame: Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.

  2. Incidence of Adverse Events (Grade 3 or Higher)

    Number of participants who experienced at least one adverse event of grade 3 or higher. Adverse events were graded and categorized using CTCAE v5.0.

    Time frame: During treatment period and up to 30 days after discontinuation of protocol therapy. The median duration of study treatment was 10 months with a range from 3 days to 55.9 months.

  3. Progression-free Survival (PFS)

    PFS was defined as the time from study entry to the first documented disease progression, or death from any cause, whichever occurs first. Disease progression was assessed by RECIST 1.1.

    Time frame: From date of protocol entry to date of first documented progression or death assessed up to approximately 55 months

  4. Overall Survival (OS)

    OS was defined as the time from study entry to death from any cause.

    Time frame: From date of protocol entry to date of death assessed up to approximately 62 months.

Other outcomes

  1. ER Expression

    Determine the expression of estrogen receptor (ER) and correlation with response and clinical benefit.

    Time frame: At time of primary and secondary outcome analysis up to 5 years.

  2. Mutation Analysis of Genomic Signatures

    Determine genomic signatures associated with response and clinical benefit of the combination of letrozole + Ribociclib

    Time frame: At time of primary and secondary outcome analysis up to 5 years

  3. PR Expression

    Determine the expression of progesterone receptor (PR) and correlation with response and clinical benefit.

    Time frame: At time of primary and secondary outcome analysis up to 5 years

  4. Ki-67 Expression

    Determine the expression of proliferative index (ki-67) and correlation with response and clinical benefit.

    Time frame: At time of primary and secondary outcome analysis up to 5 years

07

Results

Posted Dec 23, 2025

Participant flow

A total of 74 participants were screened for eligibility in the study. Out of these, 51 participants were determined to be eligible for enrollment. The recruitment period spanned from June 2018 to February of 2023.The first patient was enrolled on May 20, 2019.

Participant flow — Overall Study
MilestoneRibociclib and Letrozole
Started51
Completed49
Not completed2
Withdrew: Eligible with no protocol therapy2

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants in the analysis population who achieved a complete response or partial response, as assessed by RECIST 1.1.

Time frame:
Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsRibociclib and Letrozole
Objective Response Rate (ORR)30.6 (19.9 to 43.2)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the percentage of participants in the analysis population who achieved a complete response, partial response, or stable disease, as assessed by RECIST 1.1.

Time frame:
Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsRibociclib and Letrozole
Clinical Benefit Rate (CBR)83.7 (72.5 to 91.6)
SecondaryIncidence of Adverse Events (Grade 3 or Higher)

Number of participants who experienced at least one adverse event of grade 3 or higher. Adverse events were graded and categorized using CTCAE v5.0.

Time frame:
During treatment period and up to 30 days after discontinuation of protocol therapy. The median duration of study treatment was 10 months with a range from 3 days to 55.9 months.
Reported as:
Number · participants
Incidence of Adverse Events (Grade 3 or Higher)
participantsRibociclib and Letrozole
Blood and lymphatic system disorders2
Cardiac disorders1
Eye disorders1
Gastrointestinal disorders15
General disorders and administration site conditions2
Infections and infestations6
Injury, poisoning and procedural complications2
Investigations25
Metabolism and nutrition disorders6
Musculoskeletal and connective tissue disorders3
Nervous system disorders2
Psychiatric disorders1
Renal and urinary disorders3
Respiratory, thoracic and mediastinal disorders3
Skin and subcutaneous tissue disorders1
Vascular disorders5
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from study entry to the first documented disease progression, or death from any cause, whichever occurs first. Disease progression was assessed by RECIST 1.1.

Time frame:
From date of protocol entry to date of first documented progression or death assessed up to approximately 55 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsRibociclib and Letrozole
Progression-free Survival (PFS)14.5 (10.1 to 28.8)
SecondaryOverall Survival (OS)

OS was defined as the time from study entry to death from any cause.

Time frame:
From date of protocol entry to date of death assessed up to approximately 62 months.
Reported as:
Median · Months
Overall Survival (OS)
MonthsRibociclib and Letrozole
Overall Survival (OS)44.5 (31.8 to NA)
Other pre-specifiedER Expression

Determine the expression of estrogen receptor (ER) and correlation with response and clinical benefit.

Time frame:
At time of primary and secondary outcome analysis up to 5 years.

Results for this outcome have not been posted.

Other pre-specifiedMutation Analysis of Genomic Signatures

Determine genomic signatures associated with response and clinical benefit of the combination of letrozole + Ribociclib

Time frame:
At time of primary and secondary outcome analysis up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedPR Expression

Determine the expression of progesterone receptor (PR) and correlation with response and clinical benefit.

Time frame:
At time of primary and secondary outcome analysis up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedKi-67 Expression

Determine the expression of proliferative index (ki-67) and correlation with response and clinical benefit.

Time frame:
At time of primary and secondary outcome analysis up to 5 years

Results for this outcome have not been posted.

Adverse events

Collected over The time frame for adverse events was during treatment period and up to 30 days after discontinuation of protocol therapy. The median duration of study treatment was 10 months with a range from 3 days to 55.9 months. The time frame for all-cause mortality was from date of protocol entry to date of death, assessed up to approximately 62 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ribociclib and Letrozole22/49 (44.9%)29/49 (59.2%)49/49 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventRibociclib and Letrozole
Small Intestinal ObstructionGastrointestinal disorders6/49
Abdominal PainGastrointestinal disorders5/49
Urinary Tract InfectionInfections and infestations3/49
VomitingGastrointestinal disorders2/49
IleusGastrointestinal disorders2/49
FeverGeneral disorders2/49
HeadacheNervous system disorders2/49
DyspneaRespiratory, thoracic and mediastinal disorders2/49
AnemiaBlood and lymphatic system disorders1/49
Sinus TachycardiaCardiac disorders1/49
Most frequent other events
Showing 10 of 204
Most frequent other events
EventRibociclib and Letrozole
Neutrophil Count DecreasedInvestigations34/49
FatigueGeneral disorders30/49
NauseaGastrointestinal disorders28/49
White Blood Cell DecreasedInvestigations27/49
AnemiaBlood and lymphatic system disorders25/49
DiarrheaGastrointestinal disorders22/49
Creatinine IncreasedInvestigations22/49
Abdominal PainGastrointestinal disorders21/49
VomitingGastrointestinal disorders18/49
ConstipationGastrointestinal disorders17/49

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ribociclib and Letrozole
Age (Years) — 20-294
Age (Years) — 30-396
Age (Years) — 40-497
Age (Years) — 50-598
Age (Years) — 60-6917
Age (Years) — 70-796
Age (Years) — 80-891
Sex: Female, Male
Sex: Female, Male(Participants)Ribociclib and Letrozole
Female49
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ribociclib and Letrozole
Race — Black3
Race — White44
Race — Unknown1
Race — Declined to Report1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ribociclib and Letrozole
Ethnicity — Hispanic or Latino9
Ethnicity — Not Hispanic or Latino38
Ethnicity — Declined to Report1
Ethnicity — Unknown1
Region of Enrollment
Region of Enrollment(Participants)Ribociclib and Letrozole
United States49
Performance Status (ECOG)
Performance Status (ECOG)(Participants)Ribociclib and Letrozole
ECOG 027
ECOG 121
Not Reported1
Site of Disease
Site of Disease(Participants)Ribociclib and Letrozole
Ovary44
Peritoneum5
FIGO Stage at Diagnosis (ohr)
FIGO Stage at Diagnosis (ohr)(Participants)Ribociclib and Letrozole
I2
II1
III36
IV9
Not Reported1

4 further baseline measures are reported on the registry.

08

Study locations

27 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Dec 2024, 67 months.

Results were first posted in Dec 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 17, 2018
StartActual
May 20, 2019
Primary completionActual
Dec 23, 2024
CompletionEst.
Dec 31, 2026
Results first posted
Dec 23, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03673124
Collaborators
Novartis
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
May 20, 2019
Primary completion
Dec 23, 2024
Completion
Dec 31, 2026 (estimated)
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Study contacts

Brian Slomovitz, MD
study chair · GOG

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribociclib · Letrozole

Start the discussion